WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 319569
CAS#: 1234563-16-6 (HCl)
Description: Epetraborole, also known as GSK2251052 and AN3365, is a potent and selective leucyl-tRNA synthetase inhibitor. Epetraborole was in development for the treatment of infections caused by multidrug-resistant Gram-negative pathogens. GSK2251052 is a novel boron-containing antibiotic that inhibits bacterial leucyl tRNA synthetase. All Clostridium perfringens strains had GSK2251052 MICs of >32 μg/ml.
MedKoo Cat#: 319569
Name: Epetraborole HCl
CAS#: 1234563-16-6 (HCl)
Chemical Formula: C11H17BClNO4
Molecular Weight: 273.52
Elemental Analysis: C, 48.30; H, 6.26; B, 3.95; Cl, 12.96; N, 5.12; O, 23.40
Synonym: GSK-2251052; GSK 2251052; GSK2251052; AN3365; AN 3365; AN-3365; GSK-052; GSK 052; GSK052; Epetraborole
IUPAC/Chemical Name: (S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole hydrochloride
InChi Key: DADYQGIQOBJGIW-HNCPQSOCSA-N
InChi Code: InChI=1S/C11H16BNO4.ClH/c13-7-10-8-3-1-4-9(16-6-2-5-14)11(8)12(15)17-10;/h1,3-4,10,14-15H,2,5-7,13H2;1H/t10-;/m1./s1
SMILES Code: OB1O[C@H](CN)C2=CC=CC(OCCCO)=C21.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 273.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: O'Dwyer K, Spivak AT, Ingraham K, Min S, Holmes DJ, Jakielaszek C, Rittenhouse S, Kwan AL, Livi GP, Sathe G, Thomas E, Van Horn S, Miller LA, Twynholm M, Tomayko J, Dalessandro M, Caltabiano M, Scangarella-Oman NE, Brown JR. Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother. 2015 Jan;59(1):289-98. doi: 10.1128/AAC.03774-14. Epub 2014 Oct 27. PubMed PMID: 25348524; PubMed Central PMCID: PMC4291364.
2: Wu L, Vogt FG, Liu DQ. Flow-injection MS/MS for gas-phase chiral recognition and enantiomeric quantitation of a novel boron-containing antibiotic (GSK2251052A) by the mass spectrometric kinetic method. Anal Chem. 2013 May 21;85(10):4869-74. doi: 10.1021/ac401079x. Epub 2013 May 7. PubMed PMID: 23650921.
3: Tenero D, Bowers G, Rodvold KA, Patel A, Kurtinecz M, Dumont E, Tomayko J, Patel P. Intrapulmonary pharmacokinetics of GSK2251052 in healthy volunteers. Antimicrob Agents Chemother. 2013 Jul;57(7):3334-9. doi: 10.1128/AAC.02483-12. Epub 2013 May 6. PubMed PMID: 23650164; PubMed Central PMCID: PMC3697385.
4: Ross JE, Scangarella-Oman N, Jones RN. Determination of disk diffusion and MIC quality control guidelines for GSK2251052: a novel boron-containing antibacterial. Diagn Microbiol Infect Dis. 2013 Apr;75(4):437-9. doi: 10.1016/j.diagmicrobio.2013.01.007. Epub 2013 Feb 23. PubMed PMID: 23461830.
5: Goldstein EJ, Citron DM, Tyrrell KL, Merriam CV. Comparative in vitro activities of GSK2251052, a novel boron-containing leucyl-tRNA synthetase inhibitor, against 916 anaerobic organisms. Antimicrob Agents Chemother. 2013 May;57(5):2401-4. doi: 10.1128/AAC.02580-12. Epub 2013 Mar 4. PubMed PMID: 23459482; PubMed Central PMCID: PMC3632912.
6: Bowers GD, Tenero D, Patel P, Huynh P, Sigafoos J, O'Mara K, Young GC, Dumont E, Cunningham E, Kurtinecz M, Stump P, Conde JJ, Chism JP, Reese MJ, Yueh YL, Tomayko JF. Disposition and metabolism of GSK2251052 in humans: a novel boron-containing antibiotic. Drug Metab Dispos. 2013 May;41(5):1070-81. doi: 10.1124/dmd.112.050153. Epub 2013 Feb 25. PubMed PMID: 23439661.
7: Sutcliffe JA. Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci. 2011 Dec;1241:122-52. doi: 10.1111/j.1749-6632.2011.06323.x. Review. PubMed PMID: 22191530.
CAS#1093643-37-8 (Epetraborole free base)
CAS#1234563-15-5 (Epetraborole R-mandelate)